High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma.
We compared the effect of high-dose therapy together with autologous peripheral blood stem cell transplantation (autoPBSCT) in 60 patients with multiple myeloma (MM) with 90 patients who underwent conventional chemotherapy. We scored the prognostic factors according to our reported classification system that includes measurements of serum albumin, serum beta-2-microglobulin, and morphology of myeloma cells selected by multivariate analysis. We separated the patients into three risk groups at stratification level I (low, intermediate and high) and into two risk groups at stratification level II (low and high). AutoPBSCT tended to be as effective for high, as for low-risk patients in level I, and was obviously as helpful for high, as for low-risk patients in stratification II. In conclusion, high-risk patients with MM should be treated with high-dose therapy accompanied with autoPBSCT like low-risk patients.
Murakami
Hirokazu
H
School of Health Sciences, Faculty of Medicine, Gunma University, Showa-machi, Japan. hmura@health.gunma-u.ac.jp
Fujii
Hiroshi
H
Inaba
Tohru
T
Shimazaki
Chihiro
C
Okamoto
Sinichirou
S
Miwa
Akiyosi
A
Sawamura
Morio
M
Abe
Masahiro
M
Chou
Takaaki
T
Asaoku
Hideki
H
Kitahara
Yoshikazu
Y
Hayashi
Kunihiko
K
Kosaka
Masaaki
M
Togawa
Atsushi
A
Takatsuki
Kiyoshi
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D048429:Cell Size; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D012307:Risk Factors; D012709:Serum Albumin / Q000032:analysis; D016019:Survival Analysis; D014182:Transplantation, Autologous; D001613:beta 2-Microglobulin / Q000032:analysis
D012709:Serum Albumin; D001613:beta 2-Microglobulin